Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New AAM Chief Sets Out Priorities

US Industry Body Head Says Full Promise Of Biosimilars ‘Not Being Realized’

Executive Summary

The AAM’s new CEO, Dan Leonard, has set out his priorities for the industry association, highlighting current industry challenges as well as throwing light on how generics can be the “bridge” to a COVID-19 vaccine.

You may also be interested in...



AAM Lauds Biden’s Domestic Manufacturing Project

Executive orders signed by Joe Biden in the first days of his presidency to support the US pandemic response – including calling for a plan to bolster domestic manufacturing capabilities – have received a warm welcome from the AAM.

AAM Urges Congress To Pursue Key Legislation

AAM president and CEO Dan Leonard has written to the US Congress with five major legislative suggestions, including enforcing changes to Medicare part B and Medicare part D. 

US Industry Gears Up For Biden Administration

US off-patent industry association the AAM has welcomed the prospect of working with the incoming Biden-Harris administration, emphasizing that there is “more to be done” to improve generic and biosimilar utilization and uptake.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel